TNK: To Treat or Not to Treat

Description

The decision for or against the use of IV thrombolytics (alteplase or tenecteplase) is one of the most critical and high-risk decisions that stroke neurologists make every day.

Come hear from two of Blue Sky Telehealth’s telestroke physicians as they discuss considerations for IV thrombolytic decision making using a case-based approach.

About the Presenters

Dr. Chris Fanale joined Blue Sky in 2005. Under his leadership, telehealth services have grown from the original telehealth site in Colorado to over 300 sites nationwide. Dr. Fanale is currently the Managing Medical Director of Blue Sky Neurology as well as the Telehealth Medical Director. He has served on multiple state, regional, and national workgroups focused on the advancement of stroke care using telemedicine. He has a specific interest in optimizing stroke systems of care and the role that telemedicine can contribute to that initiative. Dr Fanale lives in Denver with his wife and three kids. He is an avid Penn State football fan, aspiring amateur chef, and loves traveling with his family.

Dr. Rich Monroe joined Blue Sky in 2021. It was during his vascular neurology fellowship that he realized the potential of telestroke to break down geographic barriers of care and became passionate about a career specifically in telestroke. His professional interests include vascular neurology and the application of neurology through telehealth. Dr. Monroe lives in New York state and enjoys spending time outside with his family–gardening, hiking, and camping.

CME Information:

This activity has been approved for AMA PRA Category 1 Credit(s)TM.

• Release Date: 7/20/23
• Expiration Date: 7/20/24
• Estimated time to complete this activity is 1 hour.